Volume 1, Issue 4 (Autumn 2020)
J Vessel Circ 2020, 1(4): 7-12 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bassirian M, Salimi A, Noori E, Moeini Z. The impact of taurolock versus heparin lock for the maintenance of central vein catheters patency in pediatric tertiary care hospitals. J Vessel Circ 2020; 1 (4) :7-12
URL: http://jvessels.muq.ac.ir/article-1-69-en.html
URL: http://jvessels.muq.ac.ir/article-1-69-en.html
1- Student Research Committee, Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran.
2- Department of Surgery, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
2- Department of Surgery, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
Abstract: (1549 Views)
Background and Aim:Central vein access is a common procedure in infants and neonates. In this regard, cutdown is a common central venous access technique. However, it is associated with complications, including catheter occlusion, infection, and spontaneous withdrawal. Catheter occlusion is a common complication of the cutdown procedure and causes catheter dysfunction and subsequent catheter removal. In this study, we compared the effect of heparin lock with Taurolock on the maintenance of central vein catheter potency placed in the greater saphenous vein at the saphenofemoral junction and their subsequent complications.
Materials and Methods:The children admitted to the pediatric hospital who required central vein access between December 2015 and July 2019 were recruited. There were two groups of patients. The first group received 0.5 mL Taurolock solution. The solution contains (cyclo)-taurolidine, heparin 500 IU/mL, and citrate (4%) before the catheter gets locked (Taurolock group). Another group received 0.5 mL heparin (contains 500 IU/mL heparin) before the catheter lock (heparin lock group). After the treatment period, the average duration of catheter usage and heparin-induced bleeding complications were evaluated.
Results: The average duration of catheter function was 13.4 days and 9.3 days in the Taurolock group, and the heparin lock group, respectively. The coagulation tests were performed on 179 patients (33.9%) during hospitalization, no heparin-induced coagulopathies were reported.
Conclusion: Using Taurolock after catheter use could significantly reduce catheter occlusion and increase the duration of catheter function. Taurolock reduces costs, prevents delays in treatment, and decreases pain sensation and discomfort in patients.
Materials and Methods:The children admitted to the pediatric hospital who required central vein access between December 2015 and July 2019 were recruited. There were two groups of patients. The first group received 0.5 mL Taurolock solution. The solution contains (cyclo)-taurolidine, heparin 500 IU/mL, and citrate (4%) before the catheter gets locked (Taurolock group). Another group received 0.5 mL heparin (contains 500 IU/mL heparin) before the catheter lock (heparin lock group). After the treatment period, the average duration of catheter usage and heparin-induced bleeding complications were evaluated.
Results: The average duration of catheter function was 13.4 days and 9.3 days in the Taurolock group, and the heparin lock group, respectively. The coagulation tests were performed on 179 patients (33.9%) during hospitalization, no heparin-induced coagulopathies were reported.
Conclusion: Using Taurolock after catheter use could significantly reduce catheter occlusion and increase the duration of catheter function. Taurolock reduces costs, prevents delays in treatment, and decreases pain sensation and discomfort in patients.
Keywords: Venous cutdown, Catheters occlusion, Heparin lock, Vascular access devices, Taurolock, Veins, Central venous catheters
Type of Study: Research |
Subject:
vascular surgery
Received: 2020/04/22 | Accepted: 2020/06/2 | Published: 2020/01/10
Received: 2020/04/22 | Accepted: 2020/06/2 | Published: 2020/01/10
References
1. [1] Zeller K, Petty J. Vascular access procedures. In: Ziegler MM, Azizkhan RG, von Allmen D, Weber TR. Operative Pediatric Surgery. 2nd ed. New York: McGraw Hill Education; 2014. https://accesssurgery.mhmedical.com/content.aspx?bookid=959&Sectionid=53539574
2. [2] Lee MM, Loyd JW. Saphenous Vein Cutdown. Treasure Island (FL): Stat Pearls Publishing; 2019. https://europepmc.org/article/NBK/nbk532880
3. [3] Stas M, Mulier S, Pattyn P, Vijgen J, De Wever I. Peroperative intravasal electrographic control of catheter tip position in access ports placed by venous cut-down technique. Eur J Surg Oncol. 2001; 27(3):316-20. [DOI:10.1053/ejso.2000.1047][PMID] [DOI:10.1053/ejso.2000.1047]
4. [4] Gauderer MWL. Vascular access techniques and devices in the pediatric patient. Surg Clin North Am. 1992; 72(6):1267-84. [DOI:10.1016/S0039-6109(16)45880-9] [DOI:10.1016/S0039-6109(16)45880-9]
5. [5] Melan NB, Wilson W, Soontharotoke CY, Koucky CJ. Saphenofemoral venous cutdowns in the premature infant. J Pediatr Surg. 1986; 21(4):341-3. [DOI:10.1016/S0022-3468(86)80199-3] [DOI:10.1016/S0022-3468(86)80199-3]
6. [6] Shockley LW, Butzier DJ. A modified wire-guided technique for venous cutdown access. Ann Emerg Med. 1990; 19(4):393-5. [DOI:10.1016/S0196-0644(05)82344-3] [DOI:10.1016/S0196-0644(05)82344-3]
7. [7] Church JT, Jarboe MD. Vascular access in the pediatric population. Surg Clin North Am. 2017; 97(1):113-28. [DOI:10.1016/j.suc.2016.08.007] [PMID] [DOI:10.1016/j.suc.2016.08.007]
8. [8] Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM, et al. Prophylactic urokinase in the management of long-term venous access devices in children: A Children's Oncology Group study. J Clin Oncol. 2004; 22(13):2718-23. [DOI:10.1200/JCO.2004.07.019] [PMID] [DOI:10.1200/JCO.2004.07.019]
9. [9] Mitchell MD, Anderson BJ, Williams K, Umscheid CA. Heparin flushing and other interventions to maintain patency of central venous catheters: A systematic review. J Adv Nurs. 2009; 65(10):2007-21. [DOI:10.1111/j.1365-2648.2009.05103.x] [PMID] [DOI:10.1111/j.1365-2648.2009.05103.x]
10. [10] Beigi AA, Seyed HadiZadeh MH, Salimi F, Ghaheri H. Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: A randomized controlled trial. Adv Biomed Res. 2014; 3:121. [DOI:10.4103/2277-9175.133192] [PMID] [PMCID] [DOI:10.4103/2277-9175.133192]
11. [11] Kulkarni M, Elsner C, Ouellet D, Zeldin R. Heparinized saline versus normal saline in maintaining patency of the radial artery catheter. Can J Surg. 1994; 37(1):37-42. [PMID]
12. [12] LeDuc K. Efficacy of normal saline solution versus heparin solution for maintaining patency of peripheral intravenous catheters in children. J Emerg Nurs. 1997; 23(4):306-9. [DOI:10.1016/S0099-1767(97)90216-6] [DOI:10.1016/S0099-1767(97)90216-6]
13. [13] Bertoglio S, Solari N, Meszaros P, Vassallo F, Bonvento M, Pastorino S, et al. Efficacy of normal saline versus heparinized saline solution for locking catheters of totally implantable long-term central vascular access devices in adult cancer patients. Cancer Nurs. 2012; 35(4):E35-42. [DOI:10.1097/NCC.0b013e31823312b1] [PMID] [DOI:10.1097/NCC.0b013e31823312b1]
14. [14] Touré A, Lauverjat M, Peraldi C, Boncompain-Gerard M, Gelas P, Barnoud D, et al. Taurolidine lock solution in the secondary prevention of central venous catheter-associated bloodstream infection in home parenteral nutrition patients. Clin Nutr. 2012; 31(4):567-70. [DOI:10.1016/j.clnu.2012.01.001] [PMID] [DOI:10.1016/j.clnu.2012.01.001]
15. [15] Liu H, Liu H, Deng J, Chen L, Yuan L, Wu Y. Preventing catheter-related bacteremia with taurolidine-citrate catheter locks: A systematic review and meta-analysis. Blood Purif. 2014; 37(3):179-87. [DOI:10.1159/000360271] [PMID] [DOI:10.1159/000360271]
16. [16] Daoud DCh, Wanten G, Joly F. Antimicrobial locks in patients receiving home parenteral nutrition. Nutrients. 2020; 12(2):439. [DOI:10.3390/nu12020439] [PMID] [PMCID] [DOI:10.3390/nu12020439]
17. [17] Al Malki H, Othman M, Osman B, Rashid A, Fituri O, Asim M. Taurolock effectively reduces tunneled dialysis catheter-related infection and catheter exchange rates among hemodialysis patients. Open J Nephrol. 2016; 6(2):55-60.[DOI:10.4236/ojneph.2016.62007] [DOI:10.4236/ojneph.2016.62007]
18. [18] Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis. 2008; 8:102. [DOI:10.1186/1471-2334-8-102] [PMID] [PMCID] [DOI:10.1186/1471-2334-8-102]
19. [19] Fontseré N, Cardozo C, Donate J, Soriano A, Muros M, Pons M, et al. Tunneled catheters with taurolidine-citrateheparin lock solution significantly improve the inflammatory profile of hemodialysis patients. Antimicrob Agents Chemother. 2014; 58(7):4180-4. [DOI:10.1128/AAC.02421-14] [PMID] [PMCID] [DOI:10.1128/AAC.02421-14]
20. [20] Kavosi Z, Sarikhani Khorrami M, Keshavarz Kh, Jafari A, Hashemi Meshkini A, Safaei HR, et al. Is Taurolidine-citrate an effective and cost-effective hemodialysis catheter lock solution? A systematic review and cost-effectiveness analysis. Med J Islam Repub Iran. 2016; 30:347. [PMID] [PMCID]
21. [21] Weijmer MC, van den Dorpel MA, Van de Ven PJG, ter Wee PM, van Geelen JACA, Groeneveld JO, et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005; 16(9):2769-77. [DOI:10.1681/ASN.2004100870] [PMID] [DOI:10.1681/ASN.2004100870]
22. [22] Zhao Y, Li Zh, Zhang L, Yang J, Yang Y, Tang Y, et al. Citrate versus heparin lock for hemodialysis catheters: A systematic review and meta-analysis of randomized controlled trials. Am J Kidney Dis. 2014; 63(3):479-90. [DOI:10.1053/j.ajkd.2013.08.016] [PMID] [DOI:10.1053/j.ajkd.2013.08.016]
23. [23] Froehlich CD, Rigby MR, Rosenberg ES, Li R, Roerig PLJ, Easley KA, et al. Ultrasound-guided central venous catheter placement decreases complications and decreases placement attempts compared with the landmark technique in patients in a pediatric intensive care unit. Crit Care Med. 2009;37(3):1090-6. [DOI:10.1097/CCM.0b013e31819b570e] [PMID] [DOI:10.1097/CCM.0b013e31819b570e]
24. [24] Wolfe RR, O'Donnell TF, Stone MD, Richmand DA, Burke JF. Investigation of factors determining the optimal glucose infusion rate in total parenteral nutrition. Metab Clin Exp.1980; 29(9):892-900. [DOI:10.1016/0026-0495(80)90130-4] [DOI:10.1016/0026-0495(80)90130-4]
25. [25] Werlin SL, Lausten T, Jessen S, Toy L, Norton A, Dallman L, et al. Treatment of central venous catheter occlusions with ethanol and hydrochloric acid. JPEN J Parenter Enteral Nutr. 1995; 19(5):416-8. [DOI:10.1177/0148607195019005416][PMID] [DOI:10.1177/0148607195019005416]
26. [26] Kerner Jr JA, Garcia‐Careaga MG, Fisher AA, Poole RL.Treatment of catheter occlusion in pediatric patients. JPEN J Parenter Enteral Nutr. 2006; 30(1S):S73-81. [DOI:10.1177/01486071060300S1S73] [PMID] [DOI:10.1177/01486071060300S1S73]
27. [27] Murphy LM, Lipman TO. Central venous catheter care in parenteral nutrition: A review. JPEN J Parenter Enteral Nutr.1987; 11(2):190-201. [DOI:10.1177/0148607187011002190][PMID] [DOI:10.1177/0148607187011002190]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2717-0357
Email: jvessels[at]muq.ac.ir
j.vessels.circul[at]gmail.com
